Fosbretabulin for the treatment of anaplastic thyroid cancer

Roberta Granata, Laura D. Locati, Lisa Licitra

Research output: Contribution to journalArticlepeer-review


Fosbretabulin tromethamine is a vascular disrupting agent, which is a type of drug that is designed to damage the vasculature (blood vessels) of cancer tumors, causing central necrosis. This drug showed activity against anaplastic thyroid cancer that was demonstrated in orthotopic xenograft models as well as in Phase I/II trials with or without carboplatin and paclitaxel combination therapy. In all of these studies, fosbretabulin was well tolerated.

Original languageEnglish
Pages (from-to)2015-2021
Number of pages7
JournalFuture Oncology
Issue number13
Publication statusPublished - Oct 1 2014


  • Anaplastic thyroid cancer
  • Fosbretabulin
  • Tubulin-binding agent

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)


Dive into the research topics of 'Fosbretabulin for the treatment of anaplastic thyroid cancer'. Together they form a unique fingerprint.

Cite this